Provided are: a peptide targeting Fusobacteria, comprising a peptide consisting of an amino acid sequence selected from the group consisting of SEQ ID NOs: 77 to 83; a composition for diagnosing cancer, comprising same; and a drug delivery composition. The peptide targeting Fusobacteria accurately targets Fusobacteria, which are harmful bacteria in various diseases, including cancer, and thus can be effectively used in cancer diagnosis and drug delivery.

The present invention is directed to the field of phage therapy for the treatment and control of bacterial infections. In particular, the present invention is directed to the novel bacteriophages F1245/05, F168/08, F170/08, F770/05, F197/08, F86/06, F87s/06 and F91a/06, isolated polypeptides thereof, compositions comprising one or more of the novel bacteriophages and/or isolated polypeptides and methods for the treatment and prevention of bacterial infection, either alone or in combination with other antibacterial therapies, e.g., antibiotics or other phage therapies.

Aspects herein concern cdtR mutations that can lead to reduced or absent virulence in C. difficile bacteria. Disclosed are compositions and methods using the cdtR mutants to treat or prevent C. difficile infections or diseases caused by C. difficile. Also disclosed are methods for detecting or determining C. difficile virulence based on mutation status of the cdtR gene in C. difficile.